Mark A. Kronenfeld
Known title: DirectorCIK: 0001578074
Associated companies
Transaction History
| PCRX | ▲ Buy | Grant | 9,999 | $0 | 6/11/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 5,230 | $0 | 6/12/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 1,775 | $0 | 6/14/2023 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 15,000 | $449K | 6/8/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 15,000 | $556K | 6/8/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 1,160 | $0 | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.